QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tcbp-announces-first-patient-completed-the-full-dose-regimen-in-achieve-clinical-trial

No TCB008-related Adverse Events seen in any of the re-start patients6 Patients received second dose, 3 Patients received third...

 tc-biopharm-closes-public-offering-of-2m-adss-and-series-g-warrants-at-1-per-ads

Warrants Priced At £0.78 Per ADS, Expiring In One Year

 why-tc-biopharm-tcbp-stock-is-down-40

TC BioPharm shares are trading lower by 44% Wednesday morning. The company announced the pricing of an offering of 2 million un...

 tc-biopharm-has-been-granted-european-patent-number-ep3283620-titled-modified-gamma-delta-cells-and-uses-thereof-for-the-treatment-of-cancer-or-infectious-diseases

https://register.epo.org/application?number=EP16721208 

 tcbp-launches-compassionate-use-program-for-tcb008

The Company's lead therapeutic will be available through a newly opened compassionate use programEDINBURGH, Scotland, May 1...

 tc-biopharm-announces-exercise-of-warrants-for-31-million-gross-proceeds

TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical stage biotechnology compa...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION